A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (NCT07266441)
A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Who can join: Review the eligibility criteria below.
Location: O Neal Comprehensive Cancer Center at UAB — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (71 Sites)
Showing the first 25 of 71 sites.
- O Neal Comprehensive Cancer Center at UAB — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- City of Hope — Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- University of California San Francisco — San Francisco, California
- Rocky Mountain Cancer Centers — Aurora, Colorado
- Colorado Blood Cancer Institute — Denver, Colorado
- Cancer Specialists of North Florida — Jacksonville, Florida
- Emory University — Atlanta, Georgia
- Northside Hospital Cancer Institute — Atlanta, Georgia
- Cancer Care Specialists of Central Illinois — O'Fallon, Illinois
- University of Iowa — Iowa City, Iowa
- Mission Cancer Blood — Waukee, Iowa
- Massachusetts General Hospital — Boston, Massachusetts
- Rutgers Cancer Institute — New Brunswick, New Jersey
- Memorial Sloan Kettering Cancer Center — New York, New York
- Levine Cancer Institute — Charlotte, North Carolina
- Cleveland Clinic Foundtation — Cleveland, Ohio
- Oncology Associates of Oregon PC Willamette Valley Cancer Institute — Eugene, Oregon
- University of Pennsylvania — Philadelphia, Pennsylvania
- SCRI Oncology Partners — Nashville, Tennessee
- Tennessee Oncology, PLLC — Nashville, Tennessee
- Texas Oncology — Austin, Texas
- MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.